173 related articles for article (PubMed ID: 9740136)
1. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy.
Olson JD; Arkin CF; Brandt JT; Cunningham MT; Giles A; Koepke JA; Witte DL
Arch Pathol Lab Med; 1998 Sep; 122(9):782-98. PubMed ID: 9740136
[TBL] [Abstract][Full Text] [Related]
2. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy.
Fairweather RB; Ansell J; van den Besselaar AM; Brandt JT; Bussey HI; Poller L; Triplett DA; White RH
Arch Pathol Lab Med; 1998 Sep; 122(9):768-81. PubMed ID: 9740135
[TBL] [Abstract][Full Text] [Related]
3. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban.
Laposata M; Green D; Van Cott EM; Barrowcliffe TW; Goodnight SH; Sosolik RC
Arch Pathol Lab Med; 1998 Sep; 122(9):799-807. PubMed ID: 9740137
[TBL] [Abstract][Full Text] [Related]
4. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: introduction.
Brandt JT
Arch Pathol Lab Med; 1998 Sep; 122(9):765-6. PubMed ID: 9740134
[No Abstract] [Full Text] [Related]
5. Current considerations in the use of the APTT in monitoring unfractionated heparin.
Nelson DE
Clin Lab Sci; 1999; 12(6):359-64. PubMed ID: 10724634
[TBL] [Abstract][Full Text] [Related]
6. Laboratory testing of anticoagulants: the present and the future.
Favaloro EJ; Lippi G; Koutts J
Pathology; 2011 Dec; 43(7):682-92. PubMed ID: 22081129
[TBL] [Abstract][Full Text] [Related]
7. College of American Pathologists Consensus Conference XXXVI: Diagnostic Issues in Thrombophilia.
Arch Pathol Lab Med; 2002 Nov; 126(11):1277-433. PubMed ID: 12421135
[TBL] [Abstract][Full Text] [Related]
8. Monitoring unfractionated heparin with the aPTT: time for a fresh look.
Eikelboom JW; Hirsh J
Thromb Haemost; 2006 Nov; 96(5):547-52. PubMed ID: 17080209
[TBL] [Abstract][Full Text] [Related]
9. Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?
Hull RD; Pineo GF
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():11-23. PubMed ID: 15085462
[TBL] [Abstract][Full Text] [Related]
10. An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin.
Favaloro EJ; Bonar R; Sioufi J; Wheeler M; Low J; Aboud M; Lloyd J; Street A; Marsden K;
Pathology; 2005 Jun; 37(3):234-8. PubMed ID: 16175898
[TBL] [Abstract][Full Text] [Related]
11. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring.
Hull RD; Pineo GF; Stein P
Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652
[TBL] [Abstract][Full Text] [Related]
12. A new plastic collection tube made of polyethylene terephtalate is suitable for monitoring traditional anticoagulant therapy (oral anticoagulant, unfractionated heparin, and low molecular weight heparin).
Toulon P; Ajzenberg N; Smahi M; Guillin MC
Thromb Res; 2007; 119(2):135-43. PubMed ID: 16426667
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin.
Spinler SA; Wittkowsky AK; Nutescu EA; Smythe MA
Ann Pharmacother; 2005; 39(7-8):1275-85. PubMed ID: 15956240
[TBL] [Abstract][Full Text] [Related]
14. Heparin cofactor II deficiency.
Tollefsen DM
Arch Pathol Lab Med; 2002 Nov; 126(11):1394-400. PubMed ID: 12421148
[TBL] [Abstract][Full Text] [Related]
15. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation monitoring.
Ng VL
Clin Lab Med; 2009 Jun; 29(2):283-304. PubMed ID: 19665679
[TBL] [Abstract][Full Text] [Related]
17. Activated partial thromboplastin time monitoring in patients receiving unfractionated heparin for venous thromboembolism in relation to clinical outcomes.
Vardi M; Laor A; Bitterman H
Thromb Haemost; 2009 Nov; 102(5):879-86. PubMed ID: 19888523
[TBL] [Abstract][Full Text] [Related]
18. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization.
Fritsma GA; Dembitzer FR; Randhawa A; Marques MB; Van Cott EM; Adcock-Funk D; Peerschke EI
Am J Clin Pathol; 2012 Jun; 137(6):904-8. PubMed ID: 22586049
[TBL] [Abstract][Full Text] [Related]
19. Monitoring heparin anticoagulation in the acute phase response.
Uprichard J; Manning RA; Laffan MA
Br J Haematol; 2010 May; 149(4):613-9. PubMed ID: 20230412
[TBL] [Abstract][Full Text] [Related]
20. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis.
Van Cott EM; Laposata M; Prins MH
Arch Pathol Lab Med; 2002 Nov; 126(11):1281-95. PubMed ID: 12421136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
